

The 12q14 microdeletion syndrome; 6 new cases confirming the role of HMGA2 in growth

Sally Ann Lynch, Nicola Foulds, Ann-Charlotte Thuresson, Amanda Collins, Göran Annerén, Bernt-Oves Hedberg, Carol Ann Delaney, James Iremonger, Caroline M Murray, John A Crolla, et al.

▶ To cite this version:

Sally Ann Lynch, Nicola Foulds, Ann-Charlotte Thuresson, Amanda Collins, Göran Annerén, et al.. The 12q14 microdeletion syndrome; 6 new cases confirming the role of HMGA2 in growth. European Journal of Human Genetics, 2011, 10.1038/ejhg.2010.215. hal-00611249

HAL Id: hal-00611249

https://hal.science/hal-00611249

Submitted on 26 Jul 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The 12q14 microdeletion syndrome; 6 new cases confirming the role of *HMGA2* in growth

S A Lynch*¹, N Foulds², AC Thuresson³, AL Collins², G Annerén³, BO Hedberg ⁴, CA Delaney⁵, J. Iremonger⁵, CM Murray⁵, JA Crolla⁶, C Costigan⁷, W Lam⁸, DR FitzPatrick^{8,9}, R Regan¹⁰, S Ennis¹⁰ & FH Sharkey⁵.

- 1. National Centre for Medical Genetics, OLCHC, Dublin 12, Ireland
- 2. Clinical Genetics, Princess Anne Hospital, Coxford Road, Southampton, UK
- 3. Dept of Genetics and Pathology, Uppsala University, Sweden
- 4. Dept of Pediatrics, Gävle Hospital, Sweden
- 5. Microarray Unit, Cytogenetics Laboratory, Western General Hospital Edinburgh, UK
- 6. Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK
- 7. Dept of Paediatric Endocrinology, OLCHC, Dublin 12
- 8. Clinical Genetics, Western General Hospital, Edinburgh, UK
- 9. MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
- 10. School of Medicine and Medical Science, University College Dublin, Ireland

Keywords: 12q14 microdeletion, array-CGH, HMGA2, short stature

Running title 12q14 microdeletion syndrome

*Corresponding author: Dr Sally Ann Lynch; Sallyann.lynch@olchc.ie

Tel 00-353-1-4096298 Fax 00353-1-4560953

ABSTRACT

We report 6 patients with array deletions encompassing 12q14. Out of a total of 2538 array investigations performed on children with developmental delay and dysmorphism in 3 diagnostic testing centres; 6 positive cases gives a frequency of 1 in 423 for this deletion syndrome. The deleted region in each of the six cases overlaps significantly with previously reported cases with microdeletions of this region. The chromosomal range of the deletions extends from 12q13.3q15. In the current study we report overlapping deletions of variable extent and size but primarily comprising chromosomal bands 12q13.3q14.1. Four of the six deletions were confirmed as de novo events. Two cases had deletions which included HMGA2 and both children had significant short stature. Neither case had osteopoikilosis despite both being deleted for LEMD3. Four cases had deletions that ended proximal to HMGA2 and all of these had much better growth. Five cases had congenital heart defects including 2 with atrial septal defects, one each with pulmonary stenosis, sub-aortic stenosis and a patent ductus. Four cases had moderate delay, two had severe developmental delay, and a further two had a diagnosis of autism. All six cases had significant speech delay with subtle facial dysmorphism.

INTRODUCTION

Chromosomal microdeletions and duplications are known to be a significant cause of developmental delay and congenital malformation in humans. In recent times the impact of array-CGH technologies has allowed the rapid identification and delineation of many new syndromic conditions in patients with idiopathic learning disability and congenital dysmorphism. Microdeletions of chromosomal region 12q14 have been associated with characteristic features that include low birth weight, failure to thrive, short stature, developmental delay and facial dysmorphism.¹⁻⁴ To date, six cases with deletions spanning this region and with similar phenotype have been reported as 12q14 microdeletion syndrome. Similar deletions have also been described in children with features of Silver-Russell syndrome and/or primordial dwarfism.⁴ The severe growth retardation in these cases is thought to be due to loss of *HMGA2* which lies within this region. Osteopoikilosis, due to deletion of the *LEMD3* gene, has been described in some but not all cases reported to date.

We present a further 6 children with developmental delay and array-CGH detected deletions within 12q14. Two of the children have deletions that included *HMGA2* and *LEMD3*. The other four have deletions that ended proximal to these two genes. The children with the more distal deletions, extending to and including *HMGA2* and *LEMD3* were severely growth retarded with growth of 4 standard deviations below the mean. Neither child had osteopoikilosis. The other four children with more proximal deletions have much milder evidence of growth retardation. Our cases confirm the association between severe growth retardation and loss of *HMGA2* and highlight the possibility that

cases of primordial dwarfism and/or Silver-Russell syndrome with developmental delay should be investigated for deletions within this region.

CLINICAL CASES

Case 1

The child, a girl, was born by caesarean section at 36 weeks weighing 2.05 kg at birth (Figure 1A). Her head circumference was 32 cm and length 45 cm. Her failure to thrive resulted in a provisional diagnosis of Silver-Russell being made, although there was no asymmetry, no café au lait patches and no history of excess sweating. She sat independently at 18 months, and she "bottom shuffled" until the age of 4 yrs when she eventually walked. She has speech delay although this is predominantly expressive. At the age of 11 yrs she is moderately developmentally delayed and is quite hyperactive, although she can concentrate. She can speak full sentences in both English and Polish, however she had significant expressive speech delay as a younger child. She cannot read or write. She can recognise colors, is good at jigsaws, and likes singing and music. She can dress herself and manage basic hygiene. She is described as a naughty but popular child. She suffers from gastrointestinal reflux and previously suffered from constipation. On examination aged 7 yrs 11 months her Ht was 101.5 cm (-4.21 SDS), Wt 14.2 (-4.42 SDS) and OFHC 53.2 cm (+1.13 SDS). Her mother and father are 161 cm and 176 cm tall respectively. She has relative macrocephaly. Her height velocity has been 3-4 cm per year. Her leg length (-2.4 SDS) is greater than her sitting height (4.9 SDS). She has a convergent squint, a high nasal bridge, long eyelashes and a cupids bow. She has clinodactyly and her terminal phalanges

are broad. She had 5th finger clinodactyly bilaterally. From the age of 10 years, she has developed truncal obesity with her weight velocity being greater than her height velocity.

Clinical Investigations

The following investigations were normal: U&E, TFTs, routine chromosome analysis, uniparental disomy for chromosome 7, MLPA telemore testing, IGF 1 18.7 nmol/l (12 – 50), and IGFBP3 2.6 mg/l (1.3 – 4.66). Cortisol levels were measured on several occasions and were always within normal limits and she produced a good cortisol response to insulin induced hypoglycaemia. A small anterior pituitary gland was seen on brain MRI and no other abnormality was detected. A skeletal survey noted a mild scoliosis but there was no evidence of osteopoikilosis. The bone age was 8 yrs 10 months at a chronological age of 10.5 yrs. An insulin tolerance test revealed growth hormone deficiency:

Overnight growth hormone levels were subnormal for growth hormone secretion with only two peaks greater than 3.3 within 12 hours (4.5 & 4.66 mg/l). A normal result is established if at least 3 peaks per night are identified⁵. As this is less than the normal range, she has recently been started on growth hormone treatment. Of note, this child suffered a fracture to her left frontal bone as a young child and this may have been a contributory factor to the growth hormone deficiency.

Case 2

The second child, a girl was born weighing 1.93 kg at 37+4 weeks (Figure 1B). She failed to thrive from birth. She was found to have an atrial septal defect. She is severely growth

retarded with growth parameters as follows: 3 months: Ht 50.2 cm (>-4SD), Wt 4.0 kg (-3SD). OFHC 37.5 cm (-2SD);17 months: Ht 67.5(>-4SD), Wt 7.5 kg(-4SD), head circumference 45.5 cm(-1.5SD); 3 yrs: Ht 81 cm(>-3.1SD), Wt 9.9 kg(-3.4SD). She still only weighed 10 kg at 3 yrs 8 months of age. The mother's height is 160 cm and her fathers 175 cm. She has failure to thrive and is currently being fed by gastrostomy. She has relative macrocephaly and is hyperactive. She has a bilateral convergent squint. She has an aversion to food and she also very rarely will take a drink. She sat independently at 1 yr and started walking at the age of 2 yrs. She has no speech but can express herself by showing what she wants. She has had several ears infections and pneumonia. She has the following dysmorphic signs, a short broad neck, frontal bossing, hypertelorism, upslanting palpebral fissures, a high nasal bridge, a short nose. The philtrum is flat, the upper lip is thin and her mouth is rather big. She has a micrognathia and low set ears. She has a single palmar crease on the left hand and a sacral dimple. X-ray at age 3 years showed no signs of skeletal/bone abnormalities. She has been diagnosed with moderate mental retardation with autism and significant behavioral difficulties. The 12q14 microdeletion was not present in the mother but DNA from a phenotypically normal father was not available for testing.

Case 3

The third case, a male was born at 39 weeks weighing 3.6 kg (Figure 1C). He had feeding difficulties as a neonate. At 4 ½ yrs of age his Ht was 101 cm (-0.6 SDS), Wt 15 kg (-1.12 SDS) and head circumference 51.5 cm (+0.79 SDS). He has moderate global developmental delay and has no speech at the age of 6 years. He walked at 2 ½ yrs. He has a mild degree of pulmonary stenosis and a progressive pectus deformity. Dysmorphic

features include long eyelashes, low post hairline, frontal hair whorl, mild brachydactyly. He has small joint hypermobility. He has poor oromotor control and constantly dribbled until the age of 4 yrs. The 12q14 microdeletion occurred as a *de novo* event.

Case 4

The fourth case, a male was born at 36 weeks weighing 1.9 kg (Figure 1D). He was diagnosed with pyloric stenosis for which he had surgery. He is severely developmentally delayed, hyperactive, and is thought to be on the autistic spectrum. At the age of 2 yrs 9 months he had no words. His growth parameters at age 2 yrs 11 months - OFC 48.5 cms 25th centile, Ht 87.5 50th cms and Wt 50th centile IUGR 4 lbs 11 oz at 36 weeks. At age 2 yrs 3 months his growth parameters were as follows: - Ht 83.5 cms (-0.66 SDS), Wt 12.7 kg (-0.05 SDS), OFC 48.5 cms (0 SDS). At age 5 yrs 8 months his height was 105.5, weight was 18.5 kg. It was not possible to measure his OFHC. He has a history of several upper respiratory tract infections as a young child. Dysmorphic features include a marked widow's peak, up slanting palpebral fissures, a pouty lower lip with protruding tongue. He has strikingly short, broad fingers and toes, particularly his thumbs. His genitalia are normal and otherwise examination was unremarkable. At 6 yrs and 5 months he has much more interaction with people around him. He has developed single words and is using sounds in addition to defining by action very well. However, he is still extremely active and still in nappies. He is not interested in food and seems to need only a little sleep. He has started to bite his arms a bit and get frustrated with communication at times. Skeletal survey showed broad spatulate tips to distal phalanges. His parents declined genetic testing but were phenotypically normal.

Case 5

The pregnancy was complicated by a car accident at 28 weeks. The baby, a boy was born weighing 2.89 kg at 36 weeks (Figure 1E). He was admitted to SCBU overnight and fed rather poorly from the beginning. At age 8 months he was diagnosed with global developmental delay. He sat at 8 months, and walked at 18 months. He has marked speech delay. He is now 20 yrs old and attends a special school. Dysmorphic features include upslanting palpebral fissures, pinched nose, high palate, flat face, broad hands, flat feet, 2/3 syndactyly. A provisional earlier diagnosis of Lujan Fryns was made. Growth at 17.7 yrs: Ht 161.9 (-0.04 SDS), Wt, 51.1 kg (-0.80 SDS), OFC 53.2 cm (-0.99SDS). He had an atrial septal defect that required closure. The 12q14 microdeletion occurred as a *de novo* event.

Case 6

The sixth case (Figure 1F) was the second child of non-consanguineous parents, born at term by emergency caesarean section for fetal distress weighing 2.85 kg. This followed an uncomplicated pregnancy. There were no feeding problems. There were concerns from the beginning as the parents noticed that he was delayed in achieving his milestones. At 2 yrs and 6 months he was diagnosed to have a moderated sub-aortic stenosis. At 4 yrs and 4 months he was assessed to have moderate global developmental delay and still not putting 2 words together. He has hypermetropia. His growth parameters were Ht 95 cm (-2.3 SDS), Wt 15.1 kg (-1.1 SDS) and OFHC 49 cm (-2.3 SDS). Dysmorphic features include brachycephaly, deep set eyes, bilateral low set posteriorly rotated ears, short nasal bridge

with an upturned nose and a long simple philtrum with thin upper lip. He has focal cortical dysplasia in insular cortex on brain MRI. The 12q14 microdeletion occurred as a *de novo* event.

METHODS

Microarray Analysis

Following initial diagnostic investigations by karyotyping and multilplex ligation dependent probe amplification (MLPA (subtelomere kits P036D and P070) MRC Holland)) where no imbalances were detected, whole genome screening was carried out using whole genome 0.5Mb 'CytoChipTM', microarrays (BlueGnome) for cases 1, & 5, SNP6.0 analysis for case 2 (Affymetrix), 44K oligo (Agilent) microarray for cases 3-4 and 135K oligo (Nimblegen) for case 6. Microarray procedures were carried out on the respective microarray platforms using standard procedures. Higher resolution screening using a 135K oligonucleotide arrays (Roche-Nimblegen) were subsequently used to more precisely define deleted breakpoints for case 1;3-6. To refine breakpoints in case 2, an Affymetrix Genome-Wide SNP Array 6.0 (Affymetrix Inc) was performed in accordance with the manufacturer's instructions. All CytoChip BAC microarrays were scanned at 10µm resolution using a GenePix Pro 5.0 array scanner (Axon) and analysed using BlueFuse for Microarrays analysis software version 3.4 (BlueGnome). All Oligo and SNP arrays were performed according to the manufacturer's protocols, scanned at 2-5 µm, and analysed using SignalMap v1.9 (135K), DNA Analytics v 4.0.76 (44K) or Genotyping Console v4.0 (SNP6.0).

Confirmation of array-CGH results

FISH techniques were performed on metaphase spreads prepared from peripheral blood for patients 1,3,& 5 and both parents wherever possible, using standard techniques.⁶
Microdeletions of 12q14 were confirmed in each case using BAC probes within each respective deleted region. In case 2, three specifically designed MLPA-probes were designed to cover the region of interest.⁷ Data analysis was performed with GeneMarker software 1.85 (SoftGenetics). The parents of case 4 declined genetic testing but were identified as being phenotypically normal. Quantitiative (Real-Time) PCR (qPCR) was carried out in quadruplicate (case 5 only) and data was analysed using the relative quantification method (ddC_T).⁸ The control used was pooled DNA from 12 normal individuals from the blood bank and the reference/endogenous control was the single copy RNase P. Microarray-CGH investigations using a Nimblegen 135K array was using for confirmatory studies in case 6.

RESULTS

Detection of deletions encompassing 12q14

The deletions in all six affected individuals were initially detected as part of an array-CGH screen for cryptic rearrangements in patients with moderate-severe learning disability and / or congenital anomalies following normal karyotype and subtelomere MLPA analysis. In total, we had 6 positive cases out of 2538 cases referred with developmental delay for array analysis, giving a frequency of 1 in 423 cases. It is not possible to estimate an overall

frequency of this deletion syndrome as the cases tested by array are a biased cohort, selected by Clinical Geneticists and would not represent the developmental delay population in general. High resolution oligo / SNP arrays were used to estimate the minimum size of the deletion breakpoints (median probe spacing ~12,524bp (135K), and ~40,000bp (44K), ~680bp (SNP6.0)), Case 1, 56,192,860 - 66,309,484bp; Case 2, 55,728,406 - 65,850,933bp; Case 3, 55,704,299 - 58,779,521bp, Case 4, 55,723,270 -61,759,877bp: Case 5, 55,508,340 - 56,797,233bp, and Case 6, 55,344,266 - 58329514 (NCBI Human Genome Build 36). The deleted region in each of the six cases (Figure 2) overlaps significantly with previously reported cases with microdeletions of this region ¹⁻⁴. In the current study, the chromosomal range of deletions extends from 12q13.3q15. With the exception of case 5 in the current study, cases 1-4;6 carry overlapping deletions of variable size but comprise chromosomal bands 12q13.3q14.1. No other copy number variants were identified elsewhere in the genome in the six cases that have not been previously been identified as high frequency CNVs in normal population studies according to the Database of Genomic Variants (http://projects.tcag.ca/variation/). FISH verification experiments were performed on metaphase spreads from cases 1;3;5 (case 2 where MLPA was performed, case 4 (parents unavailable) and case 6 where array-CGH was used for confirmation), to validate each copy number imbalance as detected by array-CGH. All FISH probes used to confirm the array-CGH findings for each of the cases were within each respectively deleted 12q region. Normal FISH signals for each probe were seen for parental cases 1;3;5 (data not shown) confirming that these 3 cases were *de novo* deletions of the 12q13.3q15 region. For case 2, the microdeletion was not identified in the mother, but father was not available for testing. The parents of case 4 declined genetic testing.

qPCR analysis using the TaqMan/Universal Probe Library sequence specific probes to RDH16, together with FISH was used to confirm the *de novo* deletion in case 5. Microarray analysis using a 135K oligo array (Nimblegen) was used to confirm a *de novo* deletion in case 6.

DISCUSSION

In the current communication we report a further 6 cases with deletions encompassing 12q14 which brings the total number to 12 reported cases. At a time when phenotypic variability is often associated with newly identified microdeletion syndromes, 12q14 deletions have been reported as a relatively uniform and constant phenotype of low birth weight, poor feeding in infancy, short stature and learning disability. 1-4 There also have been reports of some cases presenting with osteopoikilosis and skin lesions.³ A further case reported by Jurenka and van Allen, presenting with short stature, learning disability and a mixed sclerosing bone dysplasia is also suspected of a having a 12q14 microdeletion by Mari et al.² The 12q14 deletions in our cases varied in size from 1.28Mb – 10.12Mb. The apparent lack of low copy repeats near the breakpoints in each of our cases indicates that the underlying genetic mechanism of non-homologous end-joining may be responsible for recurrent deletions within this region. The number of HGNC genes within the deleted regions of all 6 cases ranged from 35-58 with 15-39 OMIM listed genes. While there is substantial genomic overlap with the previously reported 12q14 microdeletion cases, it should be reported that the shortest region of overlap (SRO) between all six cases reported in this communication differs substantially from the SRO of the reported cases in the literature. This will inevitably explain phenotypic variation between cases. The SRO of the

previously reported 12q14 microdeletion cases ¹⁻⁴ includes *HMGA2*. Genotype phenotype correlations are difficult to ascertain as only cases 1 & 2 are severely growth retarded but common characteristics seen include moderate - severe learning disability, speech delay, and congenital heart defects (not known for case 4) so it's possible that deletions of one or more of these genes could be responsible for any of these aspects of the phenotype. *DCTN2* and *KIF5A* have been associated with disruptions in axonal transport, ¹⁰⁻¹¹ so in theory haploinsufficiency could account for the neurodevelopmental anomalies seen in these cases. Congenital heart defects have not been reported in any of the 6 reported 12q14 microdeletions in the literature, this suggests that the candidate cardiac gene lies upstream of the 5' ends of previously reported cases. The largest region of overlap seen in our cases was between case 1 & 2 comprised 9.65Mb and includes both *HMGA2* and *LEMD3*.

The first report of the 12q14 microdeletion syndrome by Menten in 2007, described three patients with a deletion of 12q14 who presented with growth retardation & osteopoikilosis. There was a 3.44 Mb common deleted region which contained *LEMD3*, the causal gene for osteopoikilosis. However, growth retardation, failure to thrive and learning disability have not been reported in patients with osteopoikilosis or melorheostosis. Mari et al, described a case with primordial dwarfism and a smaller deletion of the 12q14.4 region. The child, a boy had severe pre and postnatal growth failure, and mild developmental delay. There was a history of poor feeding and failure to thrive, similar to the phenotype of primordial dwarfism or severe Silver-Russell syndrome (SRS). There was no evidence of osteopoikilosis but this child's deletion started distally to the Menten et al. cases and did

not include *LEMD3*. Buysse et al,³ described two children, one of whom had an intragenic deletion of *HMGA2* and short stature providing evidence that *HMGA2* is the likely growth gene. *HMGA2* lies at 12q14.3 which would explain the normal growth in our cases 3-6 whose deletion ended proximally. Spengler et al,⁴ identified one further case with a 12q14 deletion in a series of 20 children with a diagnosis of SRS. This child's deletion included *HMGA2* and *LEMD3* although he had no evidence of osteopoikilosis. Cases where *HMGA2* remains intact had growth within the normal centiles. This supports the proposal that *HMGA2* is the most significant gene associated with growth in this region. Loss of function of *Hmga2* in the mouse results in the *pygmy* phenotype that combines pre and postnatal growth failure, with resistance to the adipogenic effect of overfeeding. As such it has been suggested that haploinsufficiency of *HMGA2* could be associated with both reduced growth and poor feeding, failure to thrive and lack of adipose tissue that has been reported in some cases.² This would not explain poor feeding and failure to thrive that was seen in cases 3-6 in this report where *HMGA2* was not shown to be deleted.

Interestingly, case 1 had documented low overnight growth hormone levels. As this child had a significant head injury resulting in a frontal fracture as a baby, it is difficult to know if the low growth hormone levels are related to the deletion or as a result of the head injury or perhaps a combination of both events. This child has just recently commenced growth hormone therapy and we wait to see how this affects growth. The case reported by Mari et al,² had been treated with growth hormone without any obvious benefit. Growth hormone levels in the other cases have not been documented. There were some dysmorphic features common to cases 1-4 including a cupids bow upper lip, of all cases: Two of the children

(cases 1 & 3) had similar facial dysmorphism with long eyelashes and a cupids bow. A prognathic appearance is also present in cases 1-3. There was no evidence of osteopoikilosis in any of our cases despite a deletion of *LEMD3* in cases 1 & 2. Five of the 6 cases had congenital heart anomalies. Two cases had an atrial septal defect (case 2 & 5), one had pulmonary stenosis (case 3), one had subaortic stenosis and case 1 presented with a patent ductus. One child had pyloric stenosis but all bar case 6 had feeding difficulties. Interestingly, severe speech delay was noted in cases 2-6. Case 1, having expressive speech delay early on can currently speak full sentences in both Polish and English at age 11 years. Two of the cases (2 & 4) were also identified as having "autistic features". The dysmorphism in these children is subtle. They all had a cupids bow. Cases 1 & 2 had deep set eyes and a squint and these two children have a very similar facial appearance. The dysmorphism in the other 4 cases was subtle. All cases bar case 6 had a tall forehead. Cases 1, 3, 4 & 6 had arched eyebrows.

We conclude that the 12q14 microdeletion syndrome is a recurrent deletion syndrome with a dysmorphic phenotype which may be recognisable in some cases. One needs to consider the diagnosis in children with severe growth retardation and developmental delay. Our cases, particularly cases 3-6 whose growth was within normal centiles and whose deletion ended proximal to *HMGA2* provide further evidence that *HMGA2* is a good candidate gene for growth retardation. We would recommend growth hormone level measurements in other cases with deletions of *HMGA2* to see if growth hormone deficiency is a common finding. Further testing for loss of function mutations in *HMGA2* is also required to test for idiopathic short stature.

CONFLICT OF INTEREST

The authors confirm no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank all of the families for agreeing to participate in this study.

REFERENCES

- 1. Menten B, Buysse K, Zahir F *et al*: Osteopoikilosis, short stature & mental retardation as key features of a new microdeletion syndrome on 12q14. *J Med Genet* 2007; **44:** 264-268.
- 2. Mari F, Hermanns P, Giovannucci-Uzielli ML *et al*: Refinement of the 12q14 microdeletion syndrome: primordial dwarfism and developmental delay with or without osteopoikilosis. *Eur J Hum Genet* 2009; **17:** 1141-1147.
- 3. Buysse K, Reardon W, Mehta L *et al*: The 12q14 microdeletion syndrome: Additional patients and further evidence that *HMGA2* is an important genetic determinant for human height. *Eur J Med Genet* 2009; **52:** 101-117.

- 4. Spengler S, Schönherr N, Binder G *et al*: Sub microscopic chromosomal imbalances in idiopathic Silver-Russell syndrome (SRS): the SRS phenotype overlaps with the 12q14 microdeletion syndrome. *J Med Genet* Epub Sep 2009.
- 5. Brook CGD, Hindmarsh PC: Clinical Pediatric Endocrinology. Blackwell Science 4th edition, 2001.
- 6. Chong SS, Pack SD, Roschke AV *et al*: A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3. *Hum Mol Genet* 1997; **6:** 147-155.
- 7. Stern RF, Roberts RG, Mann K, Yau SC, Berg J, Ogilvie CM. Multiplex ligation-dependent probe amplification using a completely synthetic probe set. *Biotechniques* 2004; **37:** 399-405.
- 8. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C_T method. *Nat Protoc* 2008; **3:** 1101-1108.
- 9. Jurenka SB, Van Allen MI. Mixed sclerosing bone dysplasia, small stature, seizure disorder and mental retardation: a syndrome? *Am J Med Genet* 1995; **57:** 6-9.

10. LaMonte BH, Wallace KE, Holloway BA *et al*: Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. *Neuron* 2002; **34:** 715-727.

11. Fichera M, Lo Giudice M, Falco M, *et al*: Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. *Neurology* 2004; **63**: 1108-1110.

12. Hellemans J, Preobrazhenska O, Willaert A, *et al*: Loss of function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. *Nat Genet* 2004; **36:** 1213-1218.

TITLE AND LEGENDS TO FIGURES

Figure 1. Clinical photographs of 5 affected individuals with 12q14 deletions. Informed consent was obtained for publication of photographs for cases 1-4;6.

Figure 2. Schematic illustration of the six 12q14 deletions detected by array-CGH using the Ensembl browser. Deleted regions for the respective cases in this communication are shown as red bars.

Table 1. Summary of the clinical features presented in 6 patients with deletion of 12q14.

	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6
Sex	F	F	M	M	M	M
Birth wt (Kg)	2kg @ 36 wk	1.9 @ 37 wk	3.6kg @ 39 wk	1.9	2.9 @ 36wk	2.86 @ 40 wk
		+4		@36wk		
Development	Moderate	Severe delay	Moderate delay	Severe	Moderate	Moderate delay
	delay			delay	delay	
Behaviour	Pleasant &	Autism		Autism		
	friendly					
	personality					

Feeding	Poor feeder	Poor feeder-	Poor feeder	Pyloric	Poor feeder	Normal feeding
	Gastro-	gastrostomy		stenosis		
	intestinal	fed				
	reflux					
Malformations	?patent	Atrial septal	Pulmonary		Atrial	Sub-aortic
	ductus	defect	stenosis & pectus		septal	stenosis
			excavatum		defect	
Eyes	Convergent	Convergent				Hypermetropia
	squint	squint				
Speech	Expressive	No speech	No speech age 6	Single	"marked	Speech delay
	speech delay		years	words	speech	
				aged 6	delay"	
				years		

Figure 1 Photographs of Case 1-4 & 6. All have cupids bow & tall forehead. Case 1 & 2 have deep set eyes and a squint



Case 1 front & side profile





Case 2



Case 3



Case 4.



Case 6



